
NGEN
Healthcare · Biotechnology · $202.1M market cap
$1.88+0.25 (+15.3%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -35.8% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Time not confirmed | 0.01 | — | — |
| Aug 13, 2026 | Before the open | -0.09 | -0.37 | -311.1% |
| May 18, 2026 | Time not confirmed | -0.06 | -0.07 | -11.8% |
| Mar 31, 2026 | Before the open | -0.07 | -0.27 | -285.7% |
| Nov 25, 2025 | Time not confirmed | -0.04 | -0.04 | +4.2% |
| Aug 26, 2025 | Before the open | -0.06 | -0.09 | -50.0% |
| May 15, 2025 | Before the open | -0.06 | -0.04 | +33.3% |
| Nov 14, 2024 | Time not confirmed | — | -0.05 | — |
| Aug 22, 2024 | Time not confirmed | — | -0.08 | — |
| May 16, 2024 | Time not confirmed | — | -0.03 | — |
| Nov 9, 2023 | Time not confirmed | — | -0.05 | — |
| Aug 9, 2023 | Time not confirmed | — | -0.06 | — |
| May 15, 2023 | Time not confirmed | — | -0.06 | — |
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and…
| Mar 30, 2023 | Time not confirmed | — | -0.07 | — |
| Nov 14, 2022 | Time not confirmed | — | -0.05 | — |
| Aug 9, 2022 | Time not confirmed | — | -0.10 | — |
| May 12, 2022 | Time not confirmed | — | -0.08 | — |
| Feb 28, 2022 | Time not confirmed | — | -0.07 | — |
| Nov 19, 2021 | Time not confirmed | — | -0.07 | — |
| Aug 19, 2021 | Time not confirmed | — | -0.06 | — |